20 years ago, scientists for Celera Genomicsand the Human Genome Project sequenced the human genome. To accomplish this task, 30,000 genes were sequenced. It was a very big deal, and it opened the door to a new wave of biotech gene therapies.
Fast forward to today, Seattle-based companyAdaptive Biotechnologies(NASDAQ:ADPT)is sequencing the human immune system. This is far more difficult than mapping the human genome. Forget 30,000 -- your immune system houses 100 million genes. And on top of that, the company is mapping more than 30 billion immune receptors. (Adaptive has data rights to 20 billion of those receptors.)
All of this genetic sequencing requires massive amounts of computational power, artificial intelligence (AI), and machine learning. And that's whereMicrosoft(NASDAQ:MSFT) comes in.
Image source: Getty Images.
In 2017, Microsoft and Adaptive signed a collaboration agreement. The companies are uniting to create a universal blood test that will allow doctors to read your immune system and find out what diseases your body is fighting. If you have cancer, for instance, your body is aware of the threat and your immune system is fighting the cancer cells. The idea is to have a blood test that allows doctors to hack into a person's immune system and find out what it knows. This will enable doctors to diagnose diseases early before symptoms develop. This early diagnosis would enable doctors to prescribe medicines that boost the immune system and cure the disease.
Adaptive calls this technology immunoSEQ Dx. Once Adaptive has mapped the immune characteristics of several diseases, it will be possible to look at an individual's immune system and determine what, if any, diseases the person's immune system is currently fighting. The idea is that your doctor can take a blood sample and screen for infectious diseases, autoimmune disorders, and cancer. CEO Chad Robins is forecasting the arrival of the universal blood test in six to eight years.
As part of the collaboration agreement, Microsoft invested $45 million in thebiotechstart-up.At a recent price of $30 a share, Microsoft's investment in Adaptive is now worth about $135 million. But Microsoft is doing more than just providing financing and equipment to Adaptive -- the software giant has also provided people. A joint team of about 50 employees built the AI from scratch. Co-founders Chad and Harlan Robins led the team from Adaptive; Jonathan Carlson, senior director of immunomics at Microsoft, and Desney Tan, the general manager of Microsoft Healthcare, headed up the software side. Speaking at a Geekwire summit, Tan said, "We really integrated ourselves as a single team. We've got offices in each other's facilities."
While the immunoSEQ Dx project with Microsoft might be the most exciting work Adaptive is doing, it's several years away. In the meantime, the AI engine is already producing diagnostic kits for the market. Using Adaptive's clonoSEQ technology, doctors can now test for minimal residual disease (MRD) in blood cancers. The Food and Drug Administration has already cleared clonoSEQ for a blood cancer called multiple myeloma and acute lymphoblastic leukemia. The company is submitting clonoSEQ to the FDA for chronic lymphoblastic leukemia as well.
Adaptive is also using immunoSEQ to create a diagnostic kit for research labs and biotech companies. According to Adaptive, more than 2,000 academic researchers are now using its technology. More than 125 biotech companies are using immunoSEQ, and this technology has facilitated 480 clinical trials.These revenue streams brought in $26 million in the third quarter, up 52% year over year.The company is estimating $85 million in revenues for the full year.
Adaptive also received $300 million in cash fromGenentech, a subsidiary ofRoche(OTC:RHHBY), last year. Genentech wants to use Adaptive's technology as the foundation of a new treatment paradigm for cancer. The idea is to tailor an individualized treatment for each patient based on what's discovered via the patient's immune system. The Roche deal could be worth over $2 billion to Adaptive if certain commercial milestones are hit.The alliance with Microsoft and the massive Genentech deal are a real validation of the underlying science.
In 2020, Adaptive plans to submit the first immunoSEQ diagnostic kits to the FDA for review. While the "universal blood test" is several years away, Adaptive will add indications one at a time. The company is starting with Lyme disease, celiac disease, and ovarian cancer.
As Tan said, "These guys are going to change the world, and we're thrilled to be a part of it."
The rest is here:
Why Is Microsoft Investing in Adaptive Biotechnologies? - The Motley Fool
- Systemic Lupus Erythematosus (Lupus) - Who gets it? | NIAMS - February 7th, 2025
- Systemic Lupus Erythematosus (Lupus) Basics - National Institute of ... - February 7th, 2025
- Long COVID: women at greater risk compared to men could immune system differences be the cause? - The Conversation - February 7th, 2025
- What is Pemphigus? Symptoms & Causes | NIAMS - February 7th, 2025
- How the immune system influences pancreatic cancer: New interactions provide therapeutic insights - Medical Xpress - February 7th, 2025
- Mitochondrias Secret Power Unleashed in the Battle Against Inflammation - SciTechDaily - February 7th, 2025
- WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis - Nature.com - February 7th, 2025
- The role of the behavioral immune system in the expression of short and long-term orientation in young Chilean men during the COVID-19 pandemic - BMC... - February 7th, 2025
- Harvard nutritionist eats these 5 foods to keep her 'immune system strong' and 'energy high' - CNBC - February 7th, 2025
- Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing - Nature.com - February 7th, 2025
- Personalized Therapeutic Vaccine Steers the Immune System to Fight Kidney Cancer | Newswise - Newswise - February 7th, 2025
- Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma - Nature.com - February 7th, 2025
- Serotonin attenuates tumor necrosis factor-induced intestinal inflammation by interacting with human mucosal tissue - Nature.com - February 7th, 2025
- Identification of the immune infiltration and biomarkers in ulcerative colitis based on liquidliquid phase separation-related genes - Nature.com - February 7th, 2025
- FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy - Nature.com - February 7th, 2025
- Young Innovators: U of S researcher uses bat immune systems to find next generation therapies - Saskatoon Star-Phoenix - February 7th, 2025
- World Cancer Day 2025: Chronic stress, immune system, and cancer risk- How are these connected? - The Times of India - February 7th, 2025
- New research unlocks key to long-lasting immune response in cancer and chronic diseases - The Peter Doherty Institute for Infection and Immunity - February 7th, 2025
- Microbial Dynamics and Immune Response to NTHi in COPD - Physician's Weekly - February 7th, 2025
- MHE Week in Review RFK Jr. Spotlight - Managed Healthcare Executive - February 7th, 2025
- Psoriasis Basics: Overview, Symptoms, and Causes - January 27th, 2025
- Vitiligo Symptoms, Treatment & Causes | NIAMS - January 27th, 2025
- The Surprising Connection Between Obesity, Parasites, and Your Immune System - SciTechDaily - January 27th, 2025
- Versatile 69p spice that boosts immune system can go in soups, smoothies and milk - Express - January 27th, 2025
- How the skins secret immune system could lead to needle-free vaccines - Gavi, the Vaccine Alliance - January 27th, 2025
- Fevers link with a key kind of immunity is surprisingly ancient - Science News Magazine - January 27th, 2025
- Immunology - The Scientist - January 27th, 2025
- Opinion: Immune System And Ageing Why We Get More Vulnerable As We Age - ABP Live - January 27th, 2025
- 'Forever chemicals' (PFAS) may weaken immune function in children, leading to more frequent infections - U.S. Right to Know - January 27th, 2025
- Cellular Signals That Wreak Havoc in Sepsis are Revealed - LabRoots - January 27th, 2025
- New Combination Immunotherapy Targets Melanoma and Breast Cancer with Promising Results - Inside Precision Medicine - January 27th, 2025
- New Research in The Journal of Poultry Science: Trained Immunity Offers Novel Poultry Disease Prevention Strategies - PR Newswire - January 27th, 2025
- Scientists uncover how cancer cells hijack T-cells, making it harder for the body to fight back - Medical Xpress - January 27th, 2025
- MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire - January 27th, 2025
- Mitochondria may be a promising therapeutic target for inflammatory diseases - Medical Xpress - January 27th, 2025
- Explainer: What is Guillain-Barr Syndrome and how it affects the immune system - Mathrubhumi English - January 27th, 2025
- Yes, Some Vaccines Contain Aluminum. Thats a Good Thing. - The New York Times - January 27th, 2025
- You Are What You Eat? MD Breaks Down The Science Of The Gut Microbiome - mindbodygreen - January 27th, 2025
- Potential gamechanger: Researchers discover basis for immunotherapy-induced myocarditis - Healio - January 27th, 2025
- Ozempic and Wegovy may boost health, from addiction to dementia - BBC.com - January 27th, 2025
- Neutrophil diversity and function in health and disease - Nature.com - December 6th, 2024
- Harnessing the Power of the Immune System for Breast Cancer Treatment - Breast Cancer Research Foundation - December 6th, 2024
- Study Examines Neoantigen Landscapes and Their Role in Immunotherapy Efficacy - Consult QD - December 6th, 2024
- The 5 Best Teas to Support Your Immune System This Cold & Flu Season - EatingWell - December 6th, 2024
- Engineered immune cells may be able to tame inflammation - Medical Xpress - December 6th, 2024
- Hybrid model of tumor growth, angiogenesis and immune response yields strategies to improve antiangiogenic therapy - Nature.com - December 6th, 2024
- Opioids interfere with cancer immunotherapy, but another type of drug could help - Medical Xpress - December 6th, 2024
- RANKL cytokine restores thymus cells in old mice, reducing tumor growth and improving T cell immune response - Fierce Biotech - December 6th, 2024
- Predictive role of neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index for mortality in... - December 6th, 2024
- Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target... - December 6th, 2024
- Study cracks the cold case of immunotherapy resistance - News-Medical.Net - December 6th, 2024
- New immune therapy improves survival and reduces tumor burden in glioblastoma - News-Medical.Net - December 6th, 2024
- Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis - Nature.com - December 6th, 2024
- Immune Cell Breakthrough: Scientists Discover a Hidden Ally in the Fight Against Cancer - SciTechDaily - December 6th, 2024
- Rising temperatures impact the immune system of wild monkeys - Earth.com - December 6th, 2024
- Study declaring Alzheimer's to be a "brain disease" proven to be fabricated - Earth.com - December 6th, 2024
- Warming temperatures impact immune performance of wild monkeys, U-M study shows - University of Michigan News - December 6th, 2024
- New study explores heart risks of cancer immunotherapy - News-Medical.Net - December 6th, 2024
- 'Incredible' way to boost your immune system naturally and ward of colds and flu this winter - The Mirror - December 6th, 2024
- Tis the Season to Boost Your Immune System - Mix93.3 - December 6th, 2024
- A mathematical model simulating the adaptive immune response in various vaccines and vaccination strategies - Nature.com - October 14th, 2024
- Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer - Fox Chase Cancer Center - October 14th, 2024
- What Does It Mean to Be Immunocompromised? - The New York Times - October 14th, 2024
- Scientist hopes to cure Type 1 diabetes by disguising stem cells - The University of Arizona - October 14th, 2024
- Watching an infection unfold with a sphingolipid probe - Drug Discovery News - October 14th, 2024
- The cells that protect your brain against infection could also be behind some chronic diseases - BBC.com - October 14th, 2024
- On Nutrition: Foods that help strengthen the immune system - LimaOhio.com - October 14th, 2024
- An integral T cell pathway has implications for understanding sex-based immune response - Medical Xpress - October 14th, 2024
- Immune Response Linked to Lewy Body Formation - Neuroscience News - October 14th, 2024
- Are vaccines the future of cancer prevention? - Genetic Literacy Project - October 14th, 2024
- The Gut Microbiome and Autoimmunity - Inside Precision Medicine - October 14th, 2024
- Researchers discover how oral cancer cells may block the body's immune response - News-Medical.Net - September 21st, 2024
- Are Vaccines More Effective When You Believe in Them? - Greater Good Science Center at UC Berkeley - September 21st, 2024
- Researchers discover immune response to dengue can predict risk of severe reinfections - Medical Xpress - September 21st, 2024
- Texas Researchers Find Acid Walls That Shield Cancer Tumors from Bodys Immune System Response - DARKDaily.com - Laboratory News - September 21st, 2024
- Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis - Nature.com - September 21st, 2024
- A new way to reprogram immune cells and direct them toward anti-tumor immunity - MIT News - September 21st, 2024
- Unravelling the many mysteries of the immune system - Cosmos - September 21st, 2024
- Long COVID patients maintain robust immune memory two years after infection - News-Medical.Net - September 21st, 2024
- Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections - Journal of... - September 21st, 2024